Lakewood-Amedex Biotherapeutics, Inc. LABT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.64M | 2.84M | 2.51M | 2.42M | -- |
| Depreciation & Amortization | 4.80K | 4.80K | 4.80K | 4.80K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.27M | 4.12M | 3.77M | 3.92M | -- |
| Operating Income | -7.27M | -4.12M | -3.77M | -3.92M | -- |
| Income Before Tax | -7.35M | -4.23M | -3.85M | -3.96M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.35 | -4.23 | -3.85 | -3.96 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.35M | -4.23M | -3.85M | -3.96M | -- |
| EBIT | -7.27M | -4.12M | -3.77M | -3.92M | -- |
| EBITDA | -7.26M | -4.11M | -3.77M | -3.92M | -- |
| EPS Basic | -11.43 | -10.35 | -9.81 | -9.98 | -- |
| Normalized Basic EPS | -4.86 | -3.79 | -3.45 | -3.55 | -- |
| EPS Diluted | -11.43 | -10.35 | -9.81 | -9.98 | -- |
| Normalized Diluted EPS | -4.86 | -3.79 | -3.45 | -3.55 | -- |
| Average Basic Shares Outstanding | 3.52M | 2.79M | 2.79M | 2.78M | -- |
| Average Diluted Shares Outstanding | 3.52M | 2.79M | 2.79M | 2.78M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |